For research use only. Not for therapeutic Use.
PKI-166(CAT: I008784) is a potent, selective, and orally bioavailable epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with an IC₅₀ of 0.7 nM. It effectively blocks EGFR autophosphorylation in human pancreatic cancer cells and enhances the cytotoxic activity of gemcitabine in combination therapy. In vitro, PKI-166 pretreatment suppresses EGFR-driven signaling pathways, while in vivo, oral administration (100 mg/kg) significantly inhibits pancreatic tumor growth in xenograft models. Through its ability to disrupt EGFR-mediated proliferation and survival pathways, PKI-166 serves as a valuable research tool in oncology for exploring targeted therapies against EGFR-dependent cancers, particularly pancreatic carcinoma.
CAS Number | 187724-61-4 |
Synonyms | 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol |
Molecular Formula | C20H18N4O |
Purity | ≥95% |
IUPAC Name | 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol |
InChI | InChI=1S/C20H18N4O/c1-13(14-5-3-2-4-6-14)23-19-17-11-18(24-20(17)22-12-21-19)15-7-9-16(25)10-8-15/h2-13,25H,1H3,(H2,21,22,23,24)/t13-/m1/s1 |
InChIKey | XRYJULCDUUATMC-CYBMUJFWSA-N |
SMILES | CC(C1=CC=CC=C1)NC2=NC=NC3=C2C=C(N3)C4=CC=C(C=C4)O |
Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |